DE3104703C2 - - Google Patents

Info

Publication number
DE3104703C2
DE3104703C2 DE3104703A DE3104703A DE3104703C2 DE 3104703 C2 DE3104703 C2 DE 3104703C2 DE 3104703 A DE3104703 A DE 3104703A DE 3104703 A DE3104703 A DE 3104703A DE 3104703 C2 DE3104703 C2 DE 3104703C2
Authority
DE
Germany
Prior art keywords
piracetam
treatment
cytostatics
cytostatic
adriamycin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE3104703A
Other languages
German (de)
English (en)
Other versions
DE3104703A1 (de
Inventor
Peter Dr. Bottmingen Ch Truog
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Publication of DE3104703A1 publication Critical patent/DE3104703A1/de
Application granted granted Critical
Publication of DE3104703C2 publication Critical patent/DE3104703C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
DE19813104703 1980-02-13 1981-02-10 "verwendung von nootropisch-wirksamen verbindungen" Granted DE3104703A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1169/80A CH657527A5 (de) 1980-02-13 1980-02-13 Verwendung von zentralnervoes-wirksamen verbindungen in einem mittel, welches zur verhinderung oder linderung von nebenwirkungen bestimmt ist.

Publications (2)

Publication Number Publication Date
DE3104703A1 DE3104703A1 (de) 1981-11-26
DE3104703C2 true DE3104703C2 (enExample) 1989-05-24

Family

ID=4204090

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19813104703 Granted DE3104703A1 (de) 1980-02-13 1981-02-10 "verwendung von nootropisch-wirksamen verbindungen"

Country Status (7)

Country Link
US (1) US4620973A (enExample)
JP (1) JPS56128713A (enExample)
BE (1) BE887487A (enExample)
CH (1) CH657527A5 (enExample)
DE (1) DE3104703A1 (enExample)
NL (1) NL8100579A (enExample)
ZA (1) ZA81936B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2515179A1 (fr) * 1981-07-24 1983-04-29 Hoffmann La Roche Derives de pyrrolidine, leur procede de preparation, les intermediaires pour leur synthese et leur application therapeutique
DE3326724A1 (de) * 1983-07-25 1985-02-07 Boehringer Ingelheim KG, 6507 Ingelheim In 1-stellung substituierte 4-hydroxymethyl-pyrrolidinone, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen und zwischenprodukte
DE3336024A1 (de) * 1983-10-04 1985-04-18 Boehringer Ingelheim KG, 6507 Ingelheim 4-amino-l-benzyl-pyrrolidinone und ihre saeureadditionssalze, verfahren zu ihrer herstellung und arzneimittel
GB8405896D0 (en) * 1984-03-07 1984-04-11 Sandoz Ltd Organic compounds
US5232700A (en) * 1990-11-14 1993-08-03 The Administrators Of The Tulane Educational Fund Methods of prophylaxis and treatment of herpes simplex lesions utilizing piracetam as the active ingredient
US5916903A (en) * 1997-02-28 1999-06-29 Synapse Pahrmaceuticals International, Inc. Method for reducing the effects of antineoplastic disease treatment
EP1356812B1 (en) * 2000-12-28 2009-05-13 Hamilton Pharmaceuticals, Inc. Medicines for treatment and prevention of neurogenic pain
EP1379236A4 (en) * 2001-02-23 2009-01-21 Ucb Sa TREATMENT OF TICS, TREMOR AND RELATED DISORDER
JPWO2003105869A1 (ja) * 2002-06-12 2005-10-13 天藤製薬株式会社 抗癌剤副作用抑制剤
AU2007223036A1 (en) 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2288345B1 (en) 2008-04-18 2015-06-10 University College Dublin National University Of Ireland, Dublin Psycho-pharmaceuticals
US8962676B2 (en) 2009-10-22 2015-02-24 University College Dublin, National University Of Ireland, Dublin Causal therapy of diseases or conditions associated with CNS or PNS demyelination
TWI403509B (zh) * 2010-12-27 2013-08-01 Nang Kuang Pharmaceutical Co Ltd 一種用以治療癌症之藥學組合物

Also Published As

Publication number Publication date
CH657527A5 (de) 1986-09-15
US4620973A (en) 1986-11-04
DE3104703A1 (de) 1981-11-26
BE887487A (fr) 1981-08-12
JPS56128713A (en) 1981-10-08
NL8100579A (nl) 1981-09-16
ZA81936B (en) 1982-02-24
JPH0325407B2 (enExample) 1991-04-05

Similar Documents

Publication Publication Date Title
DE3104703C2 (enExample)
DE69028542T2 (de) Felbamat zur Behandlung der Lennox-Gastaut syndrome
DE69309435T2 (de) Restenosehemmer nach perkutaner koronarer arterioplastie
DE68923151T2 (de) Verwendung von Trifluormethylphenyl-Tetrahydropyridinen zur Herstellung von Arzneimitteln zur Behandlung anxio-depressiver Erkrankungen.
EP0185210B1 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
CH670952A5 (enExample)
DE69612540T2 (de) Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von Krankheiten in Zusammenhang mit aktivem Sauestoff und freien Radikalen
DE10393729T5 (de) Verfahren zur Behandlung von Emesis
EP0007597B1 (de) N-Niedrigalkylglycinamide und Sarkosinanhydrid sowie in Kombination mit bekannten tumorhemmenden Verbindungen vorliegendes Sarkosin zur Anwendung bei der Heilung von Tumoren sowie dieselben enthaltendes Mittel und Verfahren zu dessen Herstellung
DE2709506C2 (de) Verwendung von 10-Deazaminopterin zur Behandlung von Leukämie und ascitischen Tumoren
DE4340774A1 (de) Moenomycin und dessen Derivate zur Herstellung von Arzneimitteln, sowie Arzneimittel mit einem Gehalt an Moenomycin oder dessen Derivaten
EP1001756B1 (de) Synergistisch wirkende zusammensetzungen zur selektiven bekämpfung von tumorgewebe
DE69330638T2 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
EP0132595B1 (de) Tokolytisches Mittel
DE3641822A1 (de) Verwendung von dihydrophenylaminosaeurederivaten und diese enthaltende arzneimittel zur immunmodulation und cytostase
EP0285906B1 (de) Wirkstoff zur Tumorbekämpfung
DE60307327T2 (de) Verwendung von Pteridin-Derivaten für die Behandlung von erhöhtem intrakranialem Druck
EP1528922B1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose
DE4217396A1 (de) Metrifonat enthaltendes Arzneimittel
DE4442257A1 (de) Sparsomycin
DE2340515C3 (de) Oral applizierbares Präparat für die Behandlung der Mykobakteriosen Lepra und Tuberkulose
EP0442141A1 (de) Pharmazeutische Zubereitung
DE69218544T2 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen
EP1474134B1 (de) Kombinationspräparat des natrium-wasserstoff-austausch-inhibitors cariporide mit ramipril zur verhinderung bzw zur hemmung der herzinsuffizienz
EP0398171A2 (de) Verwendung von Imidazodiazepinen bei der Behandlung von neurologischen Symptomen, welche mit zirkulatorischen Störungen des Gehirns assoziiert sind

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8128 New person/name/address of the agent

Representative=s name: ZUMSTEIN SEN., F., DR. ASSMANN, E., DIPL.-CHEM. DR

8125 Change of the main classification

Ipc: A61K 31/40

D2 Grant after examination
8327 Change in the person/name/address of the patent owner

Owner name: UCB S.A., BRUESSEL/BRUXELLES, BE

8328 Change in the person/name/address of the agent

Free format text: ZUMSTEIN, F., DIPL.-CHEM. DR.RER.NAT. KLINGSEISEN, F., DIPL.-ING., PAT.-ANWAELTE, 8000 MUENCHEN

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee